UNSPSC 51432005: Bencyclane fumarate

This classification denotes a calcium channel blocker with the molecular structure C19H31NO.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, OZN2MG334O chemically known as 3-((1-benzylcycloheptyl)oxy)-n,n-dimethylpropylamine fumarate, but more commonly known as bencyclane fumarate, which bears US NIH Compound Identifier 5282403. European Medicines Agency schedules Bencyclane fumarate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00695MIG.

Most nations, for tariff and trade purposes, schedule bencyclane fumarate under HS 29221980 and SITC 51461. As of Q4 2014, BENCYCLANE FUMARATE remains US FDA's Preferred Term for this commodity. Bencyclane fumarate bears US NLM identifiers UMLS ID C0813193 and NCI Concept Code C73828. SMILES: CN(C)CCCOC1(CCCCCC1)CC2CCCCC2.C(=C/C(=O)O)\C(=O)O.

UNSPSC 51432005 Bencyclane fumarate, a Commodity code, designates a specific pharmaceutical active pharmaceutical ingredient, but recent state and local solicitations under this code show purchasing activity focused broadly on advanced life support medications, generic multi-source pharmaceuticals, and direct-to-manufacturer prescription fulfillment programs rather than bencyclane fumarate procurement specifically. State and local buyers use this code family to solicit emergency medical supplies, pharmacy benefit program medications, and wholesale pharmaceutical distribution arrangements. Issuing bodies include municipal fire-rescue departments (City of Tampa), state health and human services agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances administering on behalf of participating state and local government facilities (Minnesota Multistate Cooperative Purchasing Alliance).

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued IFB 26P00188 on April 24, 2026, for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem for Tampa Fire Rescue, with a response deadline of April 8, 2026, and an estimated contract value of $40,000. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no stated budget or timeline pending future formal solicitation. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring manufacturers to provide pricing for identified products through authorized wholesalers, with contract effectiveness July 1, 2026, and a two-year term for new vendors.